Prostate cancer (PCa) sheds cells, genetic fragments, and proteins into the bloodstream that can be used as quantitative biomarkers for diagnosis. miR-375 is one of the most useful diagnostic biomarkers. Creative Biolabs is a world leader in the field of in vitro diagnostics (IVD) antibody development. With our extensive experience and advanced platform, we provide a range of IVD assays against miR-375 marker for the diagnosis of prostate cancer.
miR-375
microRNAs (miRNAs) are evolutionarily conserved, small noncoding RNAs that are believed to play fundamental roles in various biological processes through regulation of gene expression at the level of posttranscription. MiR-375 was first identified as a pancreatic islet-specific miRNA regulating insulin secretion. However, further study revealed that miR-375 is a multifunctional miRNA participating in pancreatic islet development, glucose homeostasis, mucosal immunity, lung surfactant secretion and more importantly, tumorigenesis. Recently, miR-375 has been found significantly downregulated in multiple types of cancer and suppresses core hallmarks of cancer by targeting several important oncogenes like AEG-1, YAP1, IGF1R, and PDK1. The alteration of miR-375 in cancer is caused by a variety of mechanisms, including the dysregulation of transcription factors, aberrant promoter methylation and so on. Reduced expression of miR-375 in tissue or circulation may indicate the presence of neoplasia as well as a poor prognosis of many malignant cancers. Moreover, miR-375 stands for a promising direction for developing targeted therapies due to its capacity to inhibit tumor cell growth in vitro and in vivo.
miR-375 as Marker of Prostate Cancer
PCa is the second most frequently diagnosed cancer in men and the sixth leading cause of death from cancer in men worldwide. miRNAs are differentially expressed in prostate cancer which enables us to use them for diagnosis. miRNA signatures provide an accurate method for cancer classification. miR-375 is prevalently decreased in cancer, which indicates that miR-375 may serve as an ideal biomarker. Screening of primary tumors and biopsy samples have confirmed that miR-375 can be used to distinguish between malignant and benign hyperplasia in several organs.
miR-375 in Prostate Cancer Diagnosis
Accumulating evidence has implied the possibility of miRNAs as diagnosis or prognosis biomarkers in cancer. Recent studies highlighted the diagnostic and prognostic potential of miR-375 in prostate cancer. The serum levels of miR-375 are suggested as diagnostic and prognostic biomarkers in prostate cancer. Although tissue miRNA profiling could be an excellent diagnosis method, invasive procedures such as endoscopic biopsy, aspiration biopsy or even surgical biopsy are required to obtain specimens. Circulating miRNAs are stable and can be detected directly despite the existed ribonuclease in serum. Recent studies have elucidated the stable existence of miRNAs in circulation. miRNAs could be enveloped in microvesicles called exosomes protecting miRNAs from degradation. miRNAs could associate with Ago2, a component of RISC, and thus remain in extracellular space with high stability. Circulating miRNAs could associate with proteins in plasma, for instance, high-density lipoprotein that assists miRNAs transportation in circulation. Recent studies highlighted the diagnostic and prognostic potential of miR-375 in prostate cancer. The serum levels of miR-375 are suggested as diagnostic and prognostic biomarkers in prostate cancer.
Creative Biolabs has focused on IVD technology for years. We have experts who are able to offer high-quality IVD antibody development services and diagnostic assays against varies of markers. We are therefore confident in offering the most suitable service and finest results for our customers all over the world. If you are interested in our IVD assay services, please contact us for more details.
For Research Use Only.
